Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Nivestym
| Field | Information |
|---|---|
| Medication Name | Nivestym |
| Generic Name | Filgrastim-sndz |
| Boxed/Label Warning | Splenic Rupture, Acute Respiratory Distress Syndrome (ARDS), Allergic Reactions |
| Purpose | Stimulates the production of neutrophils, a type of white blood cell, to reduce the risk of infection in patients undergoing chemotherapy or bone marrow transplantation. |
| Mechanism of Action | Binds to the G-CSF receptor on hematopoietic cells, stimulating proliferation, differentiation, and activation of neutrophils. |
| Dosage Forms | Injection |
| Available Strengths | 300 mcg/0.5 mL, 480 mcg/0.8 mL |
| Dosage Frequency | Daily injection, as directed by a healthcare provider. Typically given until ANC (Absolute Neutrophil Count) reaches a target range. |
| Common Side Effects | Bone pain, injection site reactions, nausea, headache, fever |
| Serious Side Effects | Splenic rupture, acute respiratory distress syndrome (ARDS), allergic reactions (rash, itching, swelling, difficulty breathing), sickle cell crisis, glomerulonephritis, capillary leak syndrome, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) |
| Drug Interactions | Drugs that may potentiate the release of neutrophils, such as lithium. |
| Important Notes | Monitor blood counts regularly. Report any signs of allergic reaction, splenic pain, or respiratory distress to your healthcare provider immediately. Patients with sickle cell disease should be monitored for sickle cell crisis. |
| Storage | Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. |
| Missed Dose | Contact your healthcare provider immediately for instructions. Do not double the dose. |
| Alternatives | Filgrastim, Pegfilgrastim (Neulasta), Tbo-filgrastim (Granix) |
Nivestym Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Filgrastim (Neupogen) | Binds to the G-CSF receptor on hematopoietic cells, stimulating proliferation, differentiation, and activation of neutrophils. | A biosimilar alternative to filgrastim-sndz, requiring daily injections. |
| Pegfilgrastim (Neulasta) | Binds to the G-CSF receptor on hematopoietic cells, stimulating proliferation, differentiation, and activation of neutrophils. Pegylated form allows for longer duration of action. | A longer-acting form of filgrastim, typically requiring only one injection per chemotherapy cycle. |
| Tbo-filgrastim (Granix) | Binds to the G-CSF receptor on hematopoietic cells, stimulating proliferation, differentiation, and activation of neutrophils. | Another biosimilar alternative to filgrastim, requiring daily injections. |
Nivestym Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Bone pain | Splenic rupture |
| Injection site reactions (redness, swelling, pain) | Acute respiratory distress syndrome (ARDS) |
| Nausea | Allergic reactions (rash, itching, swelling, difficulty breathing) |
| Headache | Sickle cell crisis |
| Fever | Glomerulonephritis |
| Fatigue | Capillary Leak Syndrome |
Nivestym Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Chemotherapy-Induced Neutropenia | 5 mcg/kg per day | Adjusted based on ANC (Absolute Neutrophil Count) response. | Administer subcutaneously. Start no sooner than 24 hours after chemotherapy. |
| Bone Marrow Transplantation | 10 mcg/kg per day | Adjusted based on ANC response. | Administer intravenously or subcutaneously. Give first dose at least 24 hours after cytotoxic chemotherapy and at least 24 hours after bone marrow infusion. |
Nivestym Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $100 |
| Without Insurance (U.S.) | $1,200 – $2,700 |
| From CPS | $2,181.90 |
